Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 6/20 | 0.69 |
| ▸ | CA2 | P00918 | 6/20 | 0.69 |
| ▸ | CA9 | Q16790 | 6/20 | 0.69 |
| ▸ | CA12 | O43570 | 5/20 | 0.69 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.50 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.50 |
| ▸ | TNF | P01375 | 1/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.49 |
| ▸ | PPARG | P37231 | 5/20 | 0.46 |
| ▸ | PPARA | Q07869 | 5/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | PPARD | Q03181 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27806433 | 0.88 | CA12 (0.59) | CA1CA2CA9CA12MCL1 | |
| SCHEMBL69345 | 0.87 | TNF (0.61) | CA1CA2CA9CA12MCL1 | |
| SCHEMBL27988223 | 0.87 | TNF (0.61) | CA1CA2CA9CA12MCL1 | |
| SCHEMBL29399206 | 0.87 | TNF (0.61) | CA1CA2CA9CA12MCL1 | |
| Methylamine SCHEMBL27512754 | 0.85 | TNF (0.55) | CA1CA2CA9CA12MCL1 | |
| Formaldehyde SCHEMBL27782575 | 0.85 | TNF (0.55) | CA1CA2CA9CA12MCL1 | |
| Methane SCHEMBL29181734 | 0.85 | TNF (0.59) | CA1CA2CA9CA12MCL1 | |
| Hydrogen Sulfide SCHEMBL29156136 | 0.85 | TNF (0.59) | CA1CA2CA9CA12MCL1 | |
| SCHEMBL27937443 | 0.85 | TNF (0.59) | CA1CA2CA9CA12MCL1 | |
| SCHEMBL27542612 | 0.85 | TNF (0.59) | CA1CA2CA9CA12MCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4082538-B1 | METHODS AND COMPOSITIONS FOR TREATMENT OF MUSCLE WASTING, MUSCLE WEAKNESS, AND/OR CACHEXIA | BAYLOR COLLEGE MEDICINE (US) | 2024-02-14 | — | — | EP | disclosed |
| US-11161831-B2 | Methods and compositions for treatment of muscle wasting, muscle weakness, and/or cachexia | BAYLOR COLLEGE OF MEDICINE (US) | 2021-11-02 | — | — | US | disclosed |
| US-20200331880-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF MUSCLE WASTING, MUSCLE WEAKNESS, AND/OR CACHEXIA | BAYLOR COLLEGE OF MEDICINE | 2020-10-22 | — | — | US | disclosed |
| US-10676455-B2 | Methods and compositions for treatment of muscle wasting, muscle weakness, and/or cachexia | BAYLOR COLLEGE OF MEDICINE (US) | 2020-06-09 | — | — | US | disclosed |
| EP-3021841-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF MUSCLE WASTING, MUSCLE WEAKNESS, AND/OR CACHEXIA | Baylor College Of Medicine (US) | 2016-05-25 | — | — | EP | disclosed |
| WO-2015010107-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF MUSCLE WASTING, MUSCLE WEAKNESS, AND/OR CACHEXIA | BAYLOR COLLEGE OF MEDICINE (US) | 2015-01-22 | — | — | WO | disclosed |
| US-20150024032-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF MUSCLE WASTING, MUSCLE WEAKNESS, AND/OR CACHEXIA | BAYLOR COLLEGE OF MEDICINE | 2015-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10676455-B2 | Methods and compositions for treatment of muscle wasting, muscle weakness, and/or cachexia | PYGM, MYLK2, STAT3 | CA1 2271/4885CA2 820/4885CA9 2156/4885 |
| US-11161831-B2 | Methods and compositions for treatment of muscle wasting, muscle weakness, and/or cachexia | PYGM, MYLK2, STAT3 | CA1 2271/4885CA2 820/4885CA9 2156/4885 |
| US-20150024032-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF MUSCLE WASTING, MUSCLE WEAKNESS, AND/OR CACHEXIA | PYGM, MYLK2, STAT3 | CA1 2271/4885CA2 820/4885CA9 2156/4885 |
| US-20200331880-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF MUSCLE WASTING, MUSCLE WEAKNESS, AND/OR CACHEXIA | PYGM, MYLK2, STAT3 | CA1 2271/4885CA2 820/4885CA9 2156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.